Literature DB >> 34211769

Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer.

Georgina Fröhlich1,2, Péter Ágoston1,3, Kliton Jorgo1,3, Gábor Stelczer1, Csaba Polgár1,3, Tibor Major1,3.   

Abstract

BACKGROUND: The objective of the study was to dosimetrically compare the intensity-modulated-arc-therapy (IMAT), Cyber-Knife therapy (CK), single fraction interstitial high-dose-rate (HDR) and low-dose-rate (LDR) brachytherapy (BT) in low-risk prostate cancer.
MATERIALS AND METHODS: Treatment plans of ten patients treated with CK were selected and additional plans using IMAT, HDR and LDR BT were created on the same CT images. The prescribed dose was 2.5/70 Gy in IMAT, 8/40 Gy in CK, 21 Gy in HDR and 145 Gy in LDR BT to the prostate gland. EQD2 dose-volume parameters were calculated for each technique and compared.
RESULTS: EQD2 total dose of the prostate was significantly lower with IMAT and CK than with HDR and LDR BT, D90 was 79.5 Gy, 116.4 Gy, 169.2 Gy and 157.9 Gy (p < 0.001). However, teletherapy plans were more conformal than BT, COIN was 0.84, 0.82, 0.76 and 0.76 (p < 0.001), respectively. The D2 to the rectum and bladder were lower with HDR BT than with IMAT, CK and LDR BT, it was 66.7 Gy, 68.1 Gy, 36.0 Gy and 68.0 Gy (p = 0.0427), and 68.4 Gy, 78.9 Gy, 51.4 Gy and 70.3 Gy (p = 0.0091) in IMAT, CK, HDR and LDR BT plans, while D0.1 to the urethra was lower with both IMAT and CK than with BTs: 79.9 Gy, 88.0 Gy, 132.7 Gy and 170.6 Gy (p < 0.001). D2 to the hips was higher with IMAT and CK, than with BTs: 13.4 Gy, 20.7 Gy, 0.4 Gy and 1.5 Gy (p < 0.001), while D2 to the sigmoid, bowel bag, testicles and penile bulb was higher with CK than with the other techniques.
CONCLUSIONS: HDR monotherapy yields the most advantageous dosimetrical plans, except for the dose to the urethra, where IMAT seems to be the optimal modality in the radiotherapy of low-risk prostate cancer.
© 2021 Greater Poland Cancer Centre.

Entities:  

Keywords:  Cyberknife therapy; intensity-modulated arc therapy; interstitial high-dose-rate brachytherapy; interstitial low-dose-rate brachytherapy; prostate cancer

Year:  2021        PMID: 34211769      PMCID: PMC8241303          DOI: 10.5603/RPOR.a2021.0028

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  30 in total

Review 1.  [Pulsed dose rate brachytherapy: a method description and review of clinical application].

Authors:  Janusz Skowronek; Tomasz Piotrowski
Journal:  Przegl Lek       Date:  2002

2.  A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy.

Authors:  D Baltas; C Kolotas; K Geramani; R F Mould; G Ioannidis; M Kekchidi; N Zamboglou
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-15       Impact factor: 7.038

Review 3.  Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials.

Authors:  Daniel Lam Cham Kee; Jocelyn Gal; Alexander T Falk; Renaud Schiappa; Marie-Eve Chand; Mathieu Gautier; Jérôme Doyen; Jean-Michel Hannoun-Levi
Journal:  Cancer Treat Rev       Date:  2018-10-11       Impact factor: 12.111

4.  Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer.

Authors:  Ruijie Yang; Nan Zhao; Anyan Liao; Hao Wang; Ang Qu
Journal:  Med Dosim       Date:  2016-07-09       Impact factor: 1.482

5.  Reporting and analyzing dose distributions: a concept of equivalent uniform dose.

Authors:  A Niemierko
Journal:  Med Phys       Date:  1997-01       Impact factor: 4.071

Review 6.  Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?

Authors:  Ivan R Vogelius; Søren M Bentzen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-30       Impact factor: 7.038

7.  Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer.

Authors:  Naoya Murakami; Jun Itami; Kae Okuma; Hiroshi Marino; Keiichi Nakagawa; Tsukasa Ban; Moritoshi Nakazato; Kazuyoshi Kanai; Kuniji Naoi; Masashi Fuse
Journal:  Strahlenther Onkol       Date:  2008-10-01       Impact factor: 3.621

Review 8.  Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?

Authors:  G C Morton; P J Hoskin
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-05-30       Impact factor: 4.126

9.  Is there room for combined modality treatments? Dosimetric comparison of boost strategies for advanced head and neck and prostate cancer.

Authors:  Joanna Góra; Johannes Hopfgartner; Peter Kuess; Brigita Paskeviciute; Dietmar Georg
Journal:  J Radiat Res       Date:  2013-07       Impact factor: 2.724

10.  Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.

Authors:  Kliton Jorgo; Csaba Polgar; Tibor Major; Gabor Stelczer; Andras Herein; Tamas Pocza; Laszlo Gesztesi; Peter Agoston
Journal:  Pathol Oncol Res       Date:  2019-03-19       Impact factor: 3.201

View more
  2 in total

1.  A comparison between high dose rate brachytherapy and stereotactic body radiotherapy boost after elective pelvic irradiation for high and very high-risk prostate cancer.

Authors:  Sergey Nikolaevich Novikov; Roman Vladimirovich Novikov; Yurii Olegovich Merezhko; Mariya Yurevna Gotovchikova; Nikolai Dmitrievich Ilin; Yulia Sergeevna Melnik; Sergey Vasilevich Kanaev
Journal:  Radiat Oncol J       Date:  2022-09-30

Review 2.  The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry.

Authors:  Tibor Major; Georgina Fröhlich; Péter Ágoston; Csaba Polgár; Zoltán Takácsi-Nagy
Journal:  Strahlenther Onkol       Date:  2021-11-01       Impact factor: 3.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.